TrialThe Journal of infectious diseases2022

A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.

Michael Schwendinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.